Assessment of cholecalciferol and antihypertensive therapy concominant use in people with arterial hypertension


  • L.V. Yankouskaya Grodno State Medical University, Grodno, Republic of Belarus
  • V.A. Snezhitskiy Grodno State Medical University, Grodno, Republic of Belarus
  • S.A. Lyalikov Grodno State Medical University, Grodno, Republic of Belarus
  • L.V. Kezhun Grodno State Medical University, Grodno, Republic of Belarus



артеріальна гіпертензія, холекальциферол, антигіпертензивна терапія, діуретики


Background. The purpose of the study was to assess the effect of cholecalciferol intake at a daily dose of 2,000 IU on the serum level of 25(ОН)D total and blood pressure (BP) against the background of antihypertensive therapy in people with arterial hypertension(AH) stage II. Materials and methods. We performed a prospective, single-center study of 115 individuals with AH stage II (91 females and 24 males), mean age 50.7 ± 7.1 years. The duration of the follow-up period averaged 15.8 ± 1.8 months (from 12 to 18 months). The patients were receiving antihypertensive therapy according to the European guidelines: angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists — losartan, or diuretics (hydrochlorothiazide or indapamide) as a part of combination therapy, or calcium antagonists — amlodipine, or beta-adrenergic blockers, or their combination. Every second patient was recommended to take vitamin D in the form of cholecalciferol at a dose of 2000 IU/d daily. All subjects were performed full blood count, clinical urine examination, measure of fasting blood sugar, serum urea, serum creatinine, office systolic and diastolic blood pressure, anthropometric data, electrocardiography. Serum level of total vitamin D was determined using immunoenzymatic assay. Statistical analysis was done by using software package STATISTICA 10.0 (SN AXAR207F394425FA-Q). Results. It was found that intake of diuretics (hydrochlorothiazide at a dose of 12.5–25.0 mg or indapamide 1.5 mg) as part of combination antihypertensive therapy influenced the dynamics of serum 25(OH)D (F = 5.35; p = 0.02) and its level (F = 11.8; p = 0.0009). Dynamic SBP value was highest (–27.4 ± 17.9) in the group receiving a diuretic and cholecalciferol, which was significantly (p < 0.001) different from the comparison group. In the same group, we established a correlation relationship between dynamic SBP and length of cholecalciferol intake (R = 0.42; p = 0.023). A significant influence of both cholecalciferol (F = 4,1; p = 0.046), and diuretics (F = 14.3; p = 0.0003) on dynamic SBP was established. Conclusions. Thiazide/thiazide-like diuretics negatively influenced the improvement of serum 25(OH)D level. The combined use of cholecalciferol and diuretic at a dose of 2000 IU/day in the treatment of patients with AH II degree allowed to obtain the greatest hypotensive effect on SBP without the risk of vitamin D overdosing in the body.


Download data is not yet available.


Płudowski P, et al. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe — recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol. 2013;64(4):319-27. PMID: 24002961.

Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007 Jul;20(7):713-9. doi: 10.1016/j.amjhyper.2007.01.017.

Forouhi NG, et al. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: The Medical Research Council Ely Prospective study 1990-2000. Diabetes. 2008 Oct;57(10):2619-25. doi: 10.2337/db08-0593.

Smotkin-Tangorra M, et al. Prevalence of vitamin D insufficiency in obese children and adolescents. J Pediatr Endocrinol Metab. 2007;20:817-23. PMID: 17849744.

Gannage-Yared MH, et al. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur J Endocrinol. 2009;160:965-71. doi: 10.1530/EJE-08-0952.

Snezhitskiy VA, Yankouskaya LV, Povorozniuk VV, et al. Vitamin D deficiency/insufficiency among residents of the Western Region of Belarus suffering from cardiovascular pathology. Standardy Medyczne. Pediatria. 2012;5:577-82. (In Russian).

Kunutsor SK, Apekey TA, Steur M. Vitamin D and risk of future hypertension: meta-analysis of 283 537 participants. Eur J Epidemiol. 2013;28(3):205-21. doi: 10.1007/s10654-013-9790-2.

Beveridge LA. Effect of Vitamin D Supplementation on Blood Pressure A Systematic Review and Meta-analysis Incorporating Individual Patient Data. JAMA Intern Med. 2015 May;175(5):745-54. doi: 10.1001/jamainternmed.2015.0237.

Sugden JA, Davies JI, Witham MD, et al. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med. 2008 May;25(3):320-5. doi: 10.1111/j.1464-5491.2007.02360.x.

Grassi G, Cifkova R, Laurent S, et al. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. European Heart Journal. 2011;32:218-25. doi: 10.1093/eurheartj/ehq394.

Mancia G. ESH/ESC Guidelines for the management of arterial hypertension 2013. Journal of Hypertension. 2013 July;31(7):1281-1357. doi: 10.1097/

Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens. 2009 Oct;27(10):1948-54. doi: 10.1097/HJH.0b013e32832f075b.

Kunutsor SK. Vitamin D and high blood pressure: causal association or epiphenomenon? Eur J Epidemiol. 2014;29:1-14. doi: 10.1007/s10654-013-9874-z.

Li Y.C. Vitamin D: a negative endocrine regulator of the reninangiotensin system and blood pressure. J Ster Biochem Molec Biol. 2004 May;89-90(1-5):387-92. doi: 10.1016/j.jsbmb.2004.03.004.

Kong J. Targeted vitamin D receptor expression in juxtaglomerular cells supresses rennin expression independent of parathyroid hormone and calcium. Kidney International. 2008 Dec;74(12):1577-81. doi: 10.1038/ki.2008.452.

Kezhun LV, Yankouskaya LV. Plasma renin activity, endothelial function, and vitamin d status in women with hypertension in premenopausal and early postmenopausal periods. Zhurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta. 2014;4(48):37-42. (In Russian).

Kezhun LV, Yankouskaya LV. Role of renin-angiotensin-aldosterone system and vitamin d in development of arterial hypertension in perimenopausal women. Zhurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta. 2013;1(41):14-7. (In Russian).

Chen WR, Liyu ZY, et al. Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: A randomized placebo-controlled trial. Atherosclerosis. 2014;235(1):102-9. doi: 10.1016/j.atherosclerosis.2014.04.011.

Forman JР. Plasma 25-hydroxy vitamin D levels and risk of incident hуреrtеnsiоn. Hypertension. 2007;49(5):1063-9. doi: 10.1161/HYPERTENSIONAHA.107.087288.




How to Cite

Yankouskaya, L., Snezhitskiy, V., Lyalikov, S., & Kezhun, L. (2021). Assessment of cholecalciferol and antihypertensive therapy concominant use in people with arterial hypertension. PAIN, JOINTS, SPINE, 7(2), 55–60.



Original Researches